Clinical trials: Anti-MAG Neuropathy, open to volunteers
Anti MAG Neuropathy
This Study Aims to Investigate the Efficacy of Photobiomodulation in the Treatment of Anti-MAG-induced Peripheral Neuropathy (LASER-MAG)
Patients treated in the hematology department of the Quimper/Cornouaille Hospital Center for IgM monoclonal gammopathy with anti-MAG and symptomatic peripheral neuropathy often reach a therapeutic impasse.
- Trial name
- LASER-MAG (NCT07661667)
- Testing
- photobiomodulation
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier de Cornouaille
Charcot-Marie-Tooth, CMT1A
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
The project aims to perform both conventional nerve-conduction studies and axonal-excitability assessments using the TRONDF protocol in patients with selected forms of Charcot-Marie-Tooth disease, with comparison to individuals…
- Conditions
- Charcot-Marie-Tooth, CMT1A, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyneuropathy Associated With Anti-MAG Antibodies (Anti-MAG Polyneuropathy)
- Trial name
- CMT-NFS (NCT07461896)
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Anti-MAG Neuropathy, Peripheral Nervous System Disease
Study Evaluating the Predictive Value of the Terminal Latency Index (TLI) for Treatment Response in Patients With Anti-MAG Neuropathy
"Anti-myelin-associated glycoprotein (anti-MAG) neuropathy is a rare dysimmune peripheral neuropathy, most commonly associated with an IgM monoclonal gammopathy.
- Conditions
- Anti-MAG Neuropathy, Peripheral Nervous System Disease, Anti-Myelin-Associated Glycoprotein Antibodie
- Trial name
- PREDIMAG (NCT07794137)
- Testing
- Electroneuromyography (ENMG) and Terminal Latency Index (TLI) Assessment
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Anti-MAG IgM-associated Demyelinating Polyneuropathy
Zanubritnib and Anti-MAG Neuropathy
The MAZINGA study is a multicenter, open-label, single-arm Phase IIA clinical trial designed to evaluate the efficacy, safety, and tolerability of zanubrutinib in patients with IgM anti-myelin-associated glycoprotein (anti-MAG)…
- Trial name
- MAZINGA (NCT07392229)
- Testing
- Zanubrutinib Oral Capsule
- Where
- 7 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Ospedaliera di Padova
Immunoglobin M Anti-myelin-associated-glycoprotein Peripheral Neuropathy
Immunoglobulin M (IgM)-Anti-myelin-associated-glycoprotein(MAG) Peripheral Neuropathy Study
There is no international consensus regarding how to assess and treat patients with immunoglobulin M (IgM)-anti-myelin-associated-glycoprotein (MAG) monoclonal gammopathy associated peripheral neuropathy.
- Trial name
- NCT03918421
- Testing
- Clinical examination and patients' questionnaires regarding activity and participation (preliminary Immunogloblin M (IgM)-Rasch-built overall Disability Scale (RODS), and finalized IgM-RODS)
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- Hospices Civils de Lyon
Anti-MAG Neuropathy
Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders
Anti-MAG neuropathy is a progressively disabling orphan rare disorder due to a monoclonal immunoglobulin M(IgM) gammopathy displaying reactivity toward MAG, a glycoprotein of the peripheral nervous system.
- Trial name
- THERAMAG (NCT05136976)
- Testing
- Rituximab infusion, Premedications
- Where
- 15 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne